Bayer flags new blood thinner as $5 bln-plus opportunity The first revenue outlook for asundexian, designed to prevent thrombosis and strokes, shows Bayer's confidence that it can replace revenue from one of its pharmaceutical best-sellers, Xarelto, which is set to lose protection from key European patents in 2026. https://ift.tt/KgrPDfU
Sewage sampling results indicating no upsurge or new COVID variant in India: Dr NK Arora The sewage sampling is being done and there also we are not getting any indication that either a new variant is here or there is a possibility of an upsurge of cases in the coming days or weeks: Dr Arora https://ift.tt/mKp2Q5o
Iqvia techies build AI avatar for remote healthcare The AI avatar can do live interactions with patients and providers so that healthcare reaches remote and underdeveloped areas with a scarcity of trained healthcare professionals. https://ift.tt/mKp2Q5o